Segment 2 - Genetics and Next-Generation Sequencing

Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.

Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.

The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.